BYL719 is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, ;liitle or no effect on PI3Kβ/γ/δ.

BX517 is a novel phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

BVT-948 (SPS8I-3) is a noncompetitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) with IC50 of 0.09-1.7 uM. Results show that the effect of BVT948 (BVT.948) is to strengthen the insulin signal and has no effects on the duration of th

Brigatinib (AP-26113, AP26113) is a potent, selective, second generation ALK inhibitor with IC50 of 0.62 nM, exhibits about fivefold greater potency in vitro compared with crizotinib.

Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells.

BRD7552 is an inducer of transcription factor PDX1, which increases insulin expression.

BPTES is a selective inhibitor of Glutaminase GLS1 (KGA)

BOS172722 (BOS-172722) is a potent, selective MPS1 kinase inhibitor with biochemical IC50 of 11 nM, 100-fold selectivity over CDK2.

Bohemine is a synthetic, cell-permeable, cyclin-dependent kinase inhibitor.

BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).

BMS-813160 is a dual CCR2/CCR5 chemokine antagonist.

BMS-626529 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T-cells.

BMS-582949 is a dual action p38 Kinase Inhibitor.

BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor with IC50 value of 0.13 uM (human recombinant ACL).

BLU-782 (BLU782) is a novel potent, selective inhibitor of Activin receptor-like kinase (ALK2) mutant R206H with binding IC50 of <10 Nm.

BIBW2992 (Afatinib, Tomtovok, Tovok) irreversibly inhibits EGFR/HER2 including EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively.

Beta-guanidinopropionic acid is a novel creatine kinase inhibitor.

BC-1215 (BC1215) is a highly unique, selective E3 ligase F box component Fbxo3 inhibitor with IL1β IC50 of 0.9 ug/mL.

BAY-293 (BAY293, BAY 293) is a potent, cell-active SOS1 inhibitor that disrupts the KRAS-SOS1 interaction with IC50 of 21 nM.

BAY 87-2243 is a highly potent and selective inhibitor of hypoxia-induced HIF-1 activation.

BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex.

BAY 2402234 (BAY2402234) is a novel potent, selective, orally bioavailable DHODH inhibitor with IC50 of 1.2 nM (human full-length DHODH).

BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively.

AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.

Azeliragon is an oral, small-molecule inhibitor of RAGE.

AZD-7624 a potent, selective, inhaled p38α MAPK inhibitor for the treatment of chronic obstructive pulmonary disease.

AZD7545 is a novel, selective small-molecule inhibitor of PDHK2 (PDH kinase2) with an IC50 of 36.8 nM and 6.4 nM for PDHK1 and PDHK2 respectively.

AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 <10 nM).

AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.

AZ-33 is a inhibitor of LDH-A with an IC50 of 0.5 μM.